Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
One reason why some patients experience recurrent disease after a curative-intent treatment might be the persistence of residual tumor cells, called minimal residual disease (MRD). MRD cannot be identified by standard radiological exams or clinical evaluation. Tumor-specific alterations found in the...
Guardado en:
Autores principales: | Natasha Honoré, Rachel Galot, Cédric van Marcke, Nisha Limaye, Jean-Pascal Machiels |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e001f60a26ed43499e1d6ba8b3142e08 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Lionel Larribère, et al.
Publicado: (2021) -
Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore VH, et al.
Publicado: (2018) -
Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma
por: Kate I. Glennon, et al.
Publicado: (2021) -
BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Maha Elazezy, et al.
Publicado: (2021) -
Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
por: Paola Ulivi, et al.
Publicado: (2021)